当前位置: 首页 > 期刊 > 《医药产业资讯》 > 202024
编号:13815762
艾塞那肽微球对2型糖尿病患者胰岛素抵抗及炎症因子的影响(4)
http://www.100md.com 2020年8月25日 《中国医药导报》 202024
     [8] Garber AJ,Abrahamson MJ,Barzilay JI,et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2017 Executive Summary [J]. Endocr Pract,2017,23(2):207-238.

    [9] Kapodistria K,Tsilibary EP,Kotsopoulou E,et al. Liraglutide,a human glucagon-like peptide-1 analogue,stimulates AKT-dependent survival signalling and inhibits pancreatic β-cell apoptosis [J]. Cell Mol Med ......
上一页1 2 3 4

您现在查看是摘要页,全文长 3702 字符